GLP-1/GIP/glucagon receptor (triple)

Assets acting on this target.

Class
Triple GLP-1/GIP/glucagon receptor agonist

This mechanism targets three related receptors (for GLP-1, GIP, and glucagon) that together govern how the body manages blood sugar, appetite, and energy use. GLP-1 and GIP are gut hormones released after eating that signal the pancreas to release insulin and that also reduce appetite and slow stomach emptying. Glucagon, in contrast, is best known for raising blood sugar by signaling the liver to release stored glucose, but it also increases the rate at which the body burns energy. A single molecule engineered to activate all three receptors combines the appetite-suppressing and insulin-supporting effects of GLP-1 and GIP with the energy-expenditure-boosting effect of glucagon, aiming for greater reductions in body weight and improved metabolic markers than agents that engage only one or two of these pathways. This combined approach is being explored primarily for obesity, type 2 diabetes, and metabolic liver disease, conditions in which excess weight, insulin resistance, and abnormal fat storage are interconnected. The rationale for pursuing all three receptors together, rather than one alone, is that each contributes a distinct and complementary physiological effect on appetite, insulin release, and metabolic rate.

By indication

Related mechanisms

GLP-1/GIP/glucagon receptor (triple) drugs compared

5 drugs, stage by indication
5 drugs acting on GLP-1/GIP/glucagon receptor (triple): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
retatrutideEli LillypeptidePhase 3Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Chronic Kidney Disease; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
UBT251Novo Nordisk, United Bio-Technology (Hengqin)peptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Chronic Kidney Disease
EfocipegtrutideHanmi PharmaceuticalpeptidePhase 2Phase 2 in MASH / NASH; Phase 1 in Obesity
HM15275Hanmi PharmaceuticalpeptidePhase 2Phase 2 in Obesity; Phase 2 in Type 2 Diabetes
HRS-4729Jiangsu Hengrui Pharmaceuticals, Kailera TherapeuticspeptidePhase 2Phase 2 in Obesity

← all mechanisms